Kezar Life Sciences KZR Institutional Ownership

Ownership Summary

Collectively, these holders controlled 59.6% of Kezar Life Sciences's outstanding shares in March 2026, down from 63.0% in December 2025.

• They increased total shares held in Kezar Life Sciences by 21.33% from the prior quarter, while the number of investors in KZR decreased 2.38% year over year.
• During the quarter, 19 of these 41 funds increased positions in KZR, 9 reduced exposure, and 13 held steady.
• Combined, these investors held 4.37Mn shares in KZR for March 2026, up by 768.97K shares quarter on quarter, and down 30.12K shares year over year.
• As of March 31, 2026, the biggest holder of Kezar Life Sciences is BML Capital Management, LLC at 720.79K shares, representing 9.81% of shares outstanding.
• Leading buyers of Kezar Life Sciences shares for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (290.53K), Rangeley Capital, LLC (157.15K), MILLENNIUM MANAGEMENT LLC (142.05K), CITADEL ADVISORS LLC (59.4K), RENAISSANCE TECHNOLOGIES LLC (57.14K).
• Top sellers of KZR stock for the quarter ending March 2026 included ADAR1 Capital Management, LLC (152.95K), Vazirani Asset Management LLC (26.43K), GEODE CAPITAL MANAGEMENT, LLC (7.18K), Morgan Stanley (1.4K), Tower Research Capital LLC (TRC) (302).
• According to Business Quant data, leading holders of KZR for March 2026 are BML Capital Management, LLC (720.79K), SUVRETTA CAPITAL MANAGEMENT, LLC (716.76K), TANG CAPITAL MANAGEMENT LLC (664.31K), VANGUARD CAPITAL MANAGEMENT LLC (290.53K), Rangeley Capital, LLC (243.07K), Affinity Asset Advisors, LLC (229.08K), RENAISSANCE TECHNOLOGIES LLC (188.43K), ACADIAN ASSET MANAGEMENT LLC (151.63K), MILLENNIUM MANAGEMENT LLC (142.05K), Peapod Lane Capital LLC (126.69K).